2.42
price down icon1.62%   -0.05
after-market アフターアワーズ: 2.42
loading
前日終値:
$2.47
開ける:
$2.41
24時間の取引高:
119.30K
Relative Volume:
0.11
時価総額:
$100.97M
収益:
-
当期純損益:
$-82.60M
株価収益率:
-1.1748
EPS:
-2.06
ネットキャッシュフロー:
$-48.61M
1週間 パフォーマンス:
-19.80%
1か月 パフォーマンス:
+9.95%
6か月 パフォーマンス:
-30.77%
1年 パフォーマンス:
-29.57%
1日の値動き範囲:
Value
$2.342
$2.50
1週間の範囲:
Value
$2.342
$3.12
52週間の値動き範囲:
Value
$1.49
$6.06

Vigil Neuroscience Inc Stock (VIGL) Company Profile

Name
名前
Vigil Neuroscience Inc
Name
セクター
Healthcare (1189)
Name
電話
857-254-4445
Name
住所
100 FORGE ROAD, WATERTOWN
Name
職員
66
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
VIGL's Discussions on Twitter

VIGL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VIGL
Vigil Neuroscience Inc
2.42 100.97M 0 -82.60M -48.61M -2.06
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.79 121.85B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
698.74 76.83B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.67 37.96B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.75 30.69B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
271.80 29.71B 3.32B -860.46M -1.04B -8.32

Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-04 開始されました William Blair Outperform
2023-12-19 ダウングレード Morgan Stanley Equal-Weight → Underweight
2023-10-18 開始されました JMP Securities Mkt Outperform
2023-03-31 開始されました Mizuho Buy
2022-09-16 開始されました Wedbush Outperform
2022-08-29 開始されました H.C. Wainwright Buy
2022-02-01 開始されました Guggenheim Buy
2022-02-01 開始されました Jefferies Buy
2022-02-01 開始されました Morgan Stanley Equal-Weight
2022-02-01 開始されました Stifel Buy
すべてを表示

Vigil Neuroscience Inc (VIGL) 最新ニュース

pulisher
Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire

Feb 20, 2025
pulisher
Feb 17, 2025

What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register

Feb 17, 2025
pulisher
Feb 16, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat

Feb 14, 2025
pulisher
Feb 09, 2025

VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025
pulisher
Feb 06, 2025

VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Are Vigil Neuroscience Inc’shares a good deal? - US Post News

Feb 05, 2025
pulisher
Jan 30, 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan

Jan 30, 2025
pulisher
Jan 27, 2025

Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN

Jan 26, 2025
pulisher
Jan 26, 2025

Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa

Jan 24, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia

Jan 23, 2025
pulisher
Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan

Jan 23, 2025
pulisher
Jan 22, 2025

Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com

Jan 22, 2025
pulisher
Jan 20, 2025

Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register

Jan 20, 2025
pulisher
Jan 15, 2025

Them too in TREM2: Street keeping AD Vigil - BioWorld Online

Jan 15, 2025
pulisher
Jan 13, 2025

Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat

Jan 13, 2025
pulisher
Jan 11, 2025

Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Geode Capital Management LLC Grows Stake in Kewaunee Scientific Co. (NASDAQ:KEQU) - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World

Jan 11, 2025
pulisher
Jan 09, 2025

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - The Manila Times

Jan 09, 2025
pulisher
Jan 08, 2025

CarGurus to Present at 27th Annual Needham Growth Conference - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan

Jan 08, 2025
pulisher
Dec 30, 2024

Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa

Dec 30, 2024
pulisher
Dec 30, 2024

Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com

Dec 30, 2024
pulisher
Dec 29, 2024

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat

Dec 29, 2024
pulisher
Dec 20, 2024

Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 19, 2024

Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India

Dec 19, 2024
pulisher
Dec 19, 2024

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat

Dec 19, 2024

Vigil Neuroscience Inc (VIGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Vigil Neuroscience Inc (VIGL) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Magovcevic-Liebisch Ivana
President and CEO
Dec 19 '24
Buy
1.68
5,000
8,400
222,687
Magovcevic-Liebisch Ivana
President and CEO
Dec 18 '24
Buy
1.67
5,000
8,350
217,687
Magovcevic-Liebisch Ivana
President and CEO
Dec 05 '24
Buy
2.34
5,000
11,700
212,687
$81.55
price up icon 2.95%
$22.68
price down icon 0.31%
$33.64
price up icon 0.63%
$319.86
price down icon 1.18%
$113.03
price up icon 3.89%
biotechnology ONC
$271.80
price down icon 2.56%
大文字化:     |  ボリューム (24 時間):